Evidence mapPaperPMID 40612751Full record

ArticleInternational journal of general medicine2025

Utility of Serum Occludin as a Prognostic Biomarker of Severe Traumatic Brain Injury and Mediation Role of Acute Lung Injury: A Two-Center Prospective Cohort Study.

Shaojun Zhang, Xiufeng Ye, Mi Guo, Yidong Jin, Xuebo Zhang, Jiehao Tu, Jing Huang, Zhiqiang Lian, Fangfang You, Han Zhang

Abstract read
In one paragraph

Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shaojun ZhangEmergency Department, Shengzhou People's Hospital (Shengzhou Branch of the First Affiliated Hospital of Zhejiang University School of Medicine, the Shengzhou Hospital of Shaoxing University), Shengzhou, Zhejiang, People's Republic of China.
Xiufeng YeDepartment of Neurosurgery, Longquan People's Hospital, Longquan, Zhejiang, People's Republic of China.
Mi GuoEmergency Department, Shengzhou People's Hospital (Shengzhou Branch of the First Affiliated Hospital of Zhejiang University School of Medicine, the Shengzhou Hospital of Shaoxing University), Shengzhou, Zhejiang, People's Republic of China.
Yidong JinEmergency Department, Shengzhou People's Hospital (Shengzhou Branch of the First Affiliated Hospital of Zhejiang University School of Medicine, the Shengzhou Hospital of Shaoxing University), Shengzhou, Zhejiang, People's Republic of China.
Xuebo ZhangEmergency Department, Shengzhou People's Hospital (Shengzhou Branch of the First Affiliated Hospital of Zhejiang University School of Medicine, the Shengzhou Hospital of Shaoxing University), Shengzhou, Zhejiang, People's Republic of China.
Jiehao TuEmergency Department, Shengzhou People's Hospital (Shengzhou Branch of the First Affiliated Hospital of Zhejiang University School of Medicine, the Shengzhou Hospital of Shaoxing University), Shengzhou, Zhejiang, People's Republic of China.
Jing HuangDepartment of Neurosurgery, Longquan People's Hospital, Longquan, Zhejiang, People's Republic of China.
Zhiqiang LianDepartment of Neurosurgery, Longquan People's Hospital, Longquan, Zhejiang, People's Republic of China.
Fangfang YouDepartment of Neurosurgery, Longquan People's Hospital, Longquan, Zhejiang, People's Republic of China.
Han ZhangEmergency Department, Shengzhou People's Hospital (Shengzhou Branch of the First Affiliated Hospital of Zhejiang University School of Medicine, the Shengzhou Hospital of Shaoxing University), Shengzhou, Zhejiang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Occludin is a crucial biomarker of blood-brain barrier disruption. Here, we investigated the association between serum occludin levels and poor neurological outcomes after severe traumatic brain injury (sTBI) and the mediating effect of acute lung injury (ALI). Methods: In this two-center prospective cohort study of 246 patients with sTBI and 100 controls, the serum occludin levels were measured. In-hospital ALI and six-month post-sTBI Glasgow Outcome Scale (GOS) scores were documented. Independent factorial relationships between severity and prognosis were determined. Results: Patients showed notably enhanced serum occludin levels compared to controls. Serum occludin levels were independently associated with Glasgow coma scale (GCS) scores, and Rotterdam computed tomography (CT) scores were linearly related to the likelihood of ALI and poor prognosis (GOS scores of 1-3), as well as independently associated with ALI, poor prognosis, ordinal GOS scores, and continuous GOS scores. The association of serum occludin levels with ALI and poor prognosis was not moderated by age, sex, hypertension, diabetes, alcohol consumption, or tobacco smoking. ALI partially mediates the relationship between serum occludin level and poor prognosis. As confirmed via a series of statistical approaches, prediction models of poor prognosis and ALI incorporating serum occludin levels and their respective independent predictors performed satisfactorily. Conclusion: A significant increase in serum occludin levels following sTBI is closely correlated with trauma severity, ALI, and poor prognosis. This may partially elucidate the link between serum occludin levels and poor prognosis, thereby strengthening serum occludin as an acceptable prognostic biomarker of sTBI.

Indexed as

acute lung injurybiomarkersmediation roleoccludinprognosisseveritytraumatic brain injury

Identifiers

PMID40612751
PMCPMC12225637

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.